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Abstract
Mesenchymal stem cells (MSCs) have emerged as a potential cell-based therapy for pulmonary emphysema in animal models. Our previous
study demonstrated that human induced pluripotent stem cell–derived MSCs (iPSC-MSCs) were superior over bone marrow–derived MSCs
(BM-MSCs) in attenuating cigarette smoke (CS)-induced airspace enlargement possibly through mitochondrial transfer. This study further
investigated the effects of iPSC-MSCs on inflammation, apoptosis, and proliferation in a CS-exposed rat model and examined the effects of the
secreted paracrine factor from MSCs as another possible mechanism in an in vitro model of bronchial epithelial cells. Rats were exposed to 4%
CS for 1 hr daily for 56 days. At days 29 and 43, human iPSC-MSCs or BM-MSCs were administered intravenously. We observed significant
attenuation of CS-induced elevation of circulating 8-isoprostane and cytokine-induced neutrophil chemoattractant-1 after iPSC-MSC treatment.
In line, a superior capacity of iPSC-MSCs was also observed in ameliorating CS-induced infiltration of macrophages and neutrophils and apop-
tosis/proliferation imbalance in lung sections over BM-MSCs. In support, the conditioned medium (CdM) from iPSC-MSCs ameliorated CS med-
ium-induced apoptosis/proliferation imbalance of bronchial epithelial cells in vitro. Conditioned medium from iPSC-MSCs contained higher level
of stem cell factor (SCF) than that from BM-MSCs. Deprivation of SCF from iPSC-MSC-derived CdM led to a reduction in anti-apoptotic and
pro-proliferative capacity. Taken together, our data suggest that iPSC-MSCs may possess anti-apoptotic/pro-proliferative capacity in the in vivo
and in vitro models of CS-induced airway cell injury partly through paracrine secretion of SCF.
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Introduction
Cigarette smoke is the primary cause of chronic obstructive pul-
monary disease (COPD) [1, 2], a progressive airway inflammatory
disease characterized by persistent airflow obstruction with poor
reversibility [3]. Emphysema characterized by airspace enlargement,
lung parenchyma destruction and elasticity loss is a major cause of
the airflow obstruction [3]. Chronic obstructive pulmonary disease is
predicted to be the fourth leading cause of death by 2030 [4], but cur-
rently, no pharmacotherapies can reverse the progressive decline of
lung function [5]. The pathogenesis of COPD involves interactions
between oxidative stress, chronic inflammation, excess protease
activity and accelerated lung ageing [3, 5, 6]. Particularly, emphy-
sema is associated with increased apoptosis of various cell types in
the lung, such as endothelial cells, alveolar epithelial cells, fibroblasts
and immune cells [7], indicating that the destruction of alveolar wall
may be a result of altered apoptosis and proliferation balance.
Mesenchymal stem cells are fibroblast-like multipotent stem cells
existing in various tissues, including bone marrow (BM), amniotic
fluid, placenta, adipose tissue and umbilical cord blood [8]. Induced
pluripotent stem cells (iPSCs) are pluripotent stem cells derived from
somatic cells through transcriptional factor-induced reprogramming
[9, 10]. Induced pluripotent stem cells can differentiate into MSCs
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through an induced-differentiation protocol, providing a new source
of MSCs (iPSC-MSCs) [11]. Compared with BM-MSCs, iPSC-MSCs
have a much higher ability of proliferation without loss of differentia-
tion potential [11] and hold potential to overcome ageing-associated
impairment [12–15]. This may be particularly important for COPD as
the prevalence, morbidity and mortality of the disease are highly cor-
related with age [16–18]. iPSC-MSCs have been reported to prevent
allergic airway inflammation in mice [19]. In addition, we have
recently demonstrated that iPSC-MSCs induced a superior effect than
BM-MSCs in attenuating CS-induced emphysema in rats [20]. It is
currently unknown whether MSCs could produce beneficial effects
through promotion of anti-apoptotic activity in addition to their anti-
inflammatory activities in our model.
Despite numerous reports of effectiveness of MSCs in diverse dis-
ease models, the exact mechanism of their action remains unknown
[21]. We previously reported that iPSC-MSCs might work through
mitochondrial transfer to lung epithelium [20]. Such action requires
direct cell contact and is, therefore, restricted to small regions around
the MSCs. However, MSCs have been reported to induce paracrine
effects via release of various immunomodulators [21]. The paracrine
effect can be effective in a large radius from MSCs as it does not rely
on direct cell contact. The role of the paracrine effects is mostly dis-
cussed on their immunomodulation, i.e. the suppression of inflamma-
tion via inhibiting immune cells, such as T cells, B cells, dendritic
cells and natural killer cells [21]. Given the role of apoptosis in the
pathogenesis of COPD, airway cell apoptosis may be another site for
the paracrine effect to act on. In particular, SCF has been reported to
mediate cell survival, migration and proliferation in a cell-type-depen-
dent manner through binding to its receptor, tyrosine kinase c-Kit
[22]. This study sought to investigate the effects of iPSC-MSCs on
CS-induced inflammation, apoptosis and proliferation in the rat model
using BM-MSCs for comparison. We hypothesized that iPSC-MSCs
may ameliorate the altered apoptosis/proliferation balance through
release of SCF. The paracrine effects will be studied using CdM from
iPSC-MSCs or BM-MSCs on cigarette smoke medium (CSM)-treated
bronchial epithelial cells in vitro.
Materials and methods
Preparation of human iPSC-MSCs, human
BM-MSCs and BEAS-2B Cells
Human BM-MSCs (cat. no. PT-2501; Cambrex Bioscience, Rockland,
ME, USA) and immortalized human bronchial epithelial cell BEAS-2B
cells (American Type Culture Collection, Rockville, MD, USA) were
obtained commercially. Human iPSC-MSCs were derived based on a
previously published protocol [11]. Briefly, IMR90 fibroblast cells (Cat#
CCL-186; American Type Culture Collection, Manassas, VA, USA) were
transduced with lentiviral vectors carrying human OCT4, SOX2, NANOG
and LIN28 genes (Plasmid 16577-80; Addgene, Cambridge, MA, USA)
followed by incubation with ES culture medium on inactivated mouse
embryonic fibroblast feeder for 20 days. Colonies with human
embryonic stem cell morphology were identified as iPSCs. For
induced-differentiation, iPSCs were incubated in DMEM (Gibco, Carls-
bad, CA, USA) supplemented with 10% serum replacement medium
(Gibco), 10 ng/ml basic fibroblast growth factor (bFGF; Gibco), 10 ng/
ml platelet-derived growth factor AB (Peprotech, Rocky Hill, NH, USA),
and 10 ng/ml epidermal growth factor (EGF; Peprotech). One week
later, differentiating iPSCs were harvested, incubated with CD24-phy-
coerythrin and CD105-FITC (BD PharMingen, San Diego, CA, USA) and
sorted by a fluorescence-activated cell sorting system. The
CD24 CD105+ cells were sub-cultured in 96-well plates to select wells
containing a single cell. The clones from a single cell were serially
reseeded to obtain a confluent 175-cm2 tissue culture flask. The iPSC-
MSCs were examined for surface marker profile (CD44+, CD49a+,
CD49e+, CD73+, CD105+, CD166+, CD34, CD45 and CD133). In
addition, the differentiation capacity was tested by efficient adipogene-
sis, osteogenesis and chondrogenesis. They were then frozen down for
future experiments. Both iPSC-MSCs and BM-MSCs were cultured in
DMEM (Gibco) supplemented with 10% foetal calf serum (Gibco), bFGF
(5 ng/ml) and EGF (10 ng/ml). The BEAS-2B cells were cultured in ker-
atinocyte serum-free media K-SFM (Gibco) supplemented with EGF
(5 ng/ml) and bovine pituitary extract (50 mg/ml). All cells were main-
tained in a humidified 37°C incubator with 5% CO2.
MSC treatment of 56-day CS-exposed rats
Cigarettes (Camel, filters, 11 mg TAR and 0.8 mg nicotine) (R.J. Rey-
nolds, Winston-Salem, NC, USA) were obtained commercially. The fil-
ters of the cigarettes were removed before the experiment. Male
Sprague-Dawley rats weighted 170–200 g were purchased from the
Laboratory Animal Unit, the University of Hong Kong. The rats were
treated with 4% (v/v) CS for 1 hr/day for continuous 56 days based on
a previously described protocol [23]. Briefly, a maximum of eight rats
were placed into a ventilated 20-l-chamber; 800 ml of 100% CS was
injected into the chamber to raise the initial CS concentration to 4%.
Then, the chamber was supplied with continuous flow of 4% CS
(1 l/min.)—a gas mixture of 100% CS (40 ml/min.) and fresh air
(960 ml/min.) from two separate peristaltic pumps (Masterflex; Cole-
Parmer Instruments Co, Niles, IL, USA). The control group is exposed
to sham air (SA) by the same protocol. The whole procedure was con-
ducted in a chemical fume hood at the same time of each day. At day
29 and day 43, CS-exposed rats were intravenously injected with plain
PBS, 3 9 106 human BM-MSCs or 3 9 106 iPSC-MSCs into tail veins.
The SA group was also injected with PBS. No obvious adverse reactions
towards the injections were observed based on the daily monitoring of
general conditions. The rats were killed 24 hrs after the last CS expo-
sure. Blood was collected via cardiac puncture and placed into vacuum
tubes without EDTA. Serum was isolated by centrifugation at 1000 9 g,
4°C for 10 min. The largest lobe of left lung was firstly inflated with
1 ml formalin and then subjected to fixation, dehydration and paraffin
embedding. The procedures were approved by the Committee on the
Use of Live Animals in Teaching and Research (CULATR) of the
University of Hong Kong (CULATR 3044-13).
ELISA and enzyme immune assay
Commercial ELISA kits were used to measure the concentrations of
cytokine-induced neutrophil chemoattractant-1 (CINC-1; R&D Systems,
Minneapolis, MN, USA) and SCF (R&D Systems) in rat sera and CdM
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from MSCs. The procedures were based on instructions provided by
each manufacturer. Serum 8-isoprostane levels were measured by 8-
isoprostane express enzyme immune assay kit (Cayman Chemical
Company, Ann Arbor, MI, USA) according to manufacturer’s protocol.
As 8-isoprostane might be esterified in lipids, all samples were pre-
hydrolysed by incubating with the same volume of 15% (w/v) KOH at
40°C for 60 min. and neutralized with 1 M potassium phosphate to get
total 8-isoprostane levels.
Generation of CSM
The CSM was prepared according to a previously described method
[24]. Cigarette smoke of two filter-removed cigarettes was bubbled into
20 ml of keratinocyte medium without supplements. The medium was
filtered through a 0.22-lm filter and regarded as 100% CSM.
BM-MSCs and iPSC-MSCs CdM treatment of
CSM-treated BEAS-2B cells
The CdM was prepared as previously described [13]. Briefly, BM-MSCs
and iPSC-MSCs were replaced with DMEM without serum and supple-
ments. After 24 hrs, the medium was collected and concentrated via
centrifugation by ultrafiltration conical tubes (Amicon Ultra-15 with
membranes selective for 5 kD). The final concentration was adjusted to
20 times that of the collected CdM.
Alternatively, to investigate the effects of SCF, SCF was depleted
from iPSC-MSCs-CdM as described previously [25]. Briefly, 0.5 lg of
anti-SCF (AF-255-NA; R&D Systems) or normal human IgG control anti-
body (1-001-A; R&D Systems) were mixed with protein G-agarose
beads in PBS at 4°C for 1 hr with intermittent shaking. After centrifuga-
tion, beads were washed three times and used for immune-depletion of
SCF. iPSC-MSCs-CdM was incubated with protein G-agarose beads
immobilized with anti-SCF antibodies or control human antibody for
1 hr at 4°C. Immune complexes absorbed on protein G-agarose beads
were precipitated by centrifugation. Finally, iPSC-MSCs-CdM was col-
lected and centrifuged and then used immediately.
The BEAS-2B cells were cultured on top of coverslips in 24-well
plates. The medium was replaced by keratinocyte medium with no sup-
plements 24 hrs before the treatment. They were then treated with 2%
(v/v) CSM. BM-MSCs-CdM or iPSC-MSCs-CdM containing 3 lg of total
protein was added at the same time. After 24 hrs, the supernatant was
removed and the cells were fixed for immunohistochemical tests or ter-
minal deoxynucleotidyl transferase-mediated dUTP nick-end labelling
(TUNEL) assay. To investigate the role of SCF, the cells were treated
with SCF-depleted iPSC-MSCs-CdM or recombinant SCF (255-SC; R&D
Systems) with 2% CSM for 24 hrs in comparison with normal iPSC-
MSCs-CdM.
Immunohistochemistry and TUNEL assay
Cell apoptosis was determined via TUNEL assay using the In Situ Cell
Death Detection Kit, POD (Roche Applied Science, Mannheim, Ger-
many). For lung sections, the rehydrated sections were heated in citrate
buffer for antigen retrieval, followed by treatment of TUNEL reaction
mixture. After 1-hr incubation in 37°C in dark, the sections were
washed and mounted with fluorescent mounting medium with 40,6-dia-
midino-2-phenylindole (DAPI) (Prolong Gold antifade reagent with DAPI;
Invitrogen, Eugene, OR, USA). For BEAS-2B cells, cells were fixed with
4% paraformaldehyde in PBS, blocked with 3% H2O2 in methanol and
permeabilized with 0.1% Triton-100 in 0.1% sodium citrate before treat-
ment of TUNEL reaction mixture. Images of five fields for each slide
were captured randomly by a motorized inverted microscope (IX81-
ZDC2; Olympus, Hamburg, Germany) magnification and analysed using
AxioVision (Zeiss, Munich, Germany).
For immunohistochemical staining, paraffin-embedded lung sections
were rehydrated, antigen-retrieved and blocked through the standard
procedure. They were then incubated with goat anti-CD68 (SC-7084;
Santa Cruz, Dallas, Texas, USA), horseradish peroxidase-conjugated
secondary antibody, and 3,30-Diaminobenzidine solution in sequence.
Alternatively, for immunofluorescent staining, they were incubated with
rabbit anti-Ki67 (ab15580; Abcam, Cambridge, UK), rabbit anti-neutro-
phil elastase (NE; ab21595; Abcam) or goat anti-CC10 (sc-9772; Santa
Cruz), relevant fluorescent secondary antibodies and mounting medium
containing DAPI (Invitrogen). As for the BEAS-2B cells cultured on cov-
erslips, they were fixed with 4% paraformaldehyde in PBS, blocked by
5% bovine serum albumin and permeabilized with 0.1% Triton-100 in
PBS. The cells were then incubated with mouse anti-cytochrome c (SC-
13156; Santa Cruz), rabbit anti-Ki67 (ab15580) or goat anti-c-Kit (SC-
1494; Santa Cruz) followed by relevant fluorescent secondary antibod-
ies. The coverslips were then removed, flipped and put on a drop of
mounting medium containing DAPI (Invitrogen) on a glass slide. Images
of 10 fields for each slide were captured randomly by a motorized
inverted microscope and analysed using AxioVision (Zeiss).
The imaging analysis was performed by counting number of positive
cells and the total amount of nuclei in each field. The ratio of positive
cells to the total cell number is calculated to avoid the effect of cell
density in cell culture or lung sections.
Western blot
BEAS-2B cells were scraped and extracted for total protein (CelLytic
M mammalian cell lysis/extraction reagent; Sigma-Aldrich, St. Louis,
MI, USA) according to the manufacturer’s instructions. The proteins
(30 lg) were separated by SDS–polyacrylamide gel and then trans-
ferred onto a polyvinylidene fluoride membrane (Bio-Rad Laboratories,
Hercules, CA, USA). After blocking with 5% skim milk in Tris-buffered
saline (pH 7.4) containing 0.1% Tween-20, the membrane was incu-
bated with diluted goat anti-c-Kit (1:500) or mouse anti-b-actin
(1:5000) at 4°C overnight. The membranes were then incubated with
horseradish peroxide-conjugated anti-goat antibody (1:2000) or anti-
mouse antibody (1:2000; Dako, Glostrup, Danmark) for 1 hr at room
temperature followed by quick incubation with enhanced chemilumi-
nescence. Target proteins were developed as bands on x-ray films
(Fujifilm, Tokyo, Japan).
Statistical analysis
Numerical data are presented as mean  S.E.M. Statistical analysis
was performed using GraphPad Prism 6.0 (GraphPad Software Inc,
San Diego, CA, USA). Differences between groups were evaluated by
Student’s t-test or one-way ANOVA followed by Newman–Keuls test
when appropriate. Significant difference was defined as when
P < 0.05.
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Results
iPSC-MSCs attenuated CS-induced macrophage
and neutrophil infiltration in the lung of rats
CD68 is a transmembrane glycoprotein highly expressed by monocytes
and tissue macrophages [26]. In order to illustrate the CS-induced infil-
tration of macrophages in lung tissues, immunohistochemistry staining
was performed against CD68 in lung sections (Fig. 1A). Cigarette
smoke exposure significantly elevated number of macrophages com-
pared with SA group (21.3  1.9 versus 2.0  0.41%; P < 0.01)
(Fig. 1C). Both treatments of iPSC-MSCs and BM-MSCs showed signif-
icant reduction in the number of macrophages compared with CS
group (4.3  0.8% for iPSC-MSCs and 12.3  1.3% for BM-MSCs,
respectively; P < 0.01 in comparison with CS group) with superior
effect by iPSC-MSCs (P < 0.01; Fig. 1C).
To examine infiltration of neutrophil in the lung, lung sections
were stained for NE (Fig. 1B). Cigarette smoke increased the number
of infiltrated neutrophils as NE-positive cells in the lung (10.2  0.7
versus 1.2  0.2%; P < 0.01; Fig. 1D). Both BM-MSCs and iPSC-
MSCs reduced the number of neutrophils (6.2  0.4 and
3.6  0.2% for BM-MSCs and iPSC-MSCs, respectively; P < 0.01
compared with CS group). iPSC-MSCs group demonstrated less neu-
trophils than BM-MSCs group (P < 0.01).
In this study, CS exposure led to a trend of elevation of serum 8-
isoprostane levels but not reaching significance compared with SA
group (2.11  0.32 ng/ml versus 1.63  0.08 ng/ml) (Fig. 1E). The
iPSC-MSCs treatment significantly reduced the serum levels of 8-iso-
prostane compared with the CS group (1.23  0.16 ng/ml for iPSC-
MSCs group, P < 0.05). Meanwhile, the BM-MSCs treatment did not
show such attenuation (1.94  0.38 ng/ml for BM-MSCs group).
Cigarette smoke exposure significantly elevated CINC-1 levels
compared with SA group (164.9  17.13 pg/ml versus
85.21  13.56 pg/ml; P < 0.05) in serum (Fig. 1F), which was atten-
uated by treatment of iPSC-MSCs (107.2  13.84 pg/ml; P < 0.05).
BM-MSCs treatment also showed a trend of decrease but not reach-
ing significance (101.8  24.5 pg/ml).
iPSC-MSCs reduced apoptosis and promoted
proliferation in CS-exposed rat lung epithelium
Cells undergoing apoptosis in alveolar regions of lung sections were
labelled green by TUNEL reaction (Fig. 2A). Cigarette smoke treat-
ment significantly increased the number of TUNEL-positive cells in
lung sections (12  2% versus 0.8  0.2%; P < 0.01; Fig. 2C). The
increase was attenuated by both iPSC-MSCs and BM-MSCs treat-
ments (3.8  0.8% and 7.4  1%; P < 0.01 in comparison with CS
group; Fig. 2C). The iPSC-MSCs group demonstrated significantly
fewer number of apoptotic cells than BM-MSCs group (P < 0.01),
indicating a better anti-apoptotic effect of iPSC-MSCs.
Proliferative cells in alveoli were labelled red by staining against
Ki-67, a marker of proliferation [27] (Fig. 2B). The rate of proliferative
cells was significantly reduced by CS exposure compared with SA
group (2.2  0.37% versus 14.8  0.8%; P < 0.01; Fig. 2D). Both
BM-MSCs and iPSC-MSCs treatments increased rate of proliferative
cell compared with CS group (5.8  0.6% and 10.4  0.5% for BM-
MSCs and iPSC-MSCs, respectively; P < 0.01 compared with CS
group; Fig. 2D). iPSC-MSCs group demonstrated higher rate of prolif-
erative cells than BM-MSCs (P < 0.01; Fig. 2D).
Furthermore, we co-stained TUNEL and Clara cell 10-kD protein
(CC-10), a marker of epithelium, to determine the apoptosis in epithe-
lium (Fig. 2E). Cigarette smoke exposure increased the number of
apoptotic cells in epithelium (5.2  0.7% versus 0.4  0.2%;
P < 0.01), which was reduced by the treatment of BM-MSCs
(3.4  0.5%; P < 0.01 in comparison to CS group) or iPSC-MSCs
(2.0  0.6%; P < 0.01 in comparison to CS group) (Fig. 2G). The
iPSC-MSCs group also showed significantly lower rate of apoptotic
cells in epithelium than BM-MSCs group (P < 0.01; Fig. 2G).
Cigarette smoke exposure also induced a reduction in proliferation
in epithelium, which was shown by co-staining against CC-10 and Ki-
67 (Fig. 2F). Cigarette smoke exposure reduced the number of prolif-
erative cells in epithelium (5.5  0.5% versus 25.8  2.8%;
P < 0.01), which was ameliorated by the treatment of BM-MSCs
(11.2  0.8%; P < 0.01 in comparison to CS group) or iPSC-MSCs
(15.2  2.3%; P < 0.01 in comparison to CS group; Fig. 2H). The
iPSC-MSCs group demonstrated higher proliferative activity in
epithelium than the BM-MSC group (P < 0.01; Fig. 2H).
iPSC-MSCs-CdM reduced apoptosis and
promoted proliferation in CSM-treated BEAS-2B
cells
BEAS-2B cells were treated with 2% CSM and CdM for 24 hr, and cell
apoptosis was determined by TUNEL assay (Fig. 3B). The 2% CSM
treatment increased the percentage of apoptotic cells (16.2  2%
versus 1.4  0.4%; P < 0.01), which was attenuated by both BM-
MSCs-CdM (9.3  0.7%; P < 0.01 in comparison to CSM group)
and iPSC-MSCs-CdM (5.5  0.5%; P < 0.01 in comparison to CSM
group; Fig. 3E). The iPSC-MSCs-CdM group exhibited fewer apoptotic
Fig. 1 Effects of MSCs on CS-induced oxidative stress and inflammation in rats. Rats (SA: n = 8, CS: n = 6, BM-MSCs: n = 7, iPSC-MSCs: n = 7)
were exposed to 4% CS 1 hr/day for 56 days. 3 9 106 BM-MSCs or iPSC-MSCs were injected at days 29 and 43. (A) Tissue macrophages as
CD68-positive cells with brown staining in the lung. Nuclei were stained blue by haematoxylin. (B) Tissue neutrophils as neutrophil elastase (NE)-
positive cells with green fluorescence. Nuclei were stained blue with DAPI. (C) Ratio of CD68-positive cells in the lung sections. (D) Ratio of NE-
positive cells in the lung sections. (E) 8-isoprostane levels and (F) CINC-1 levels in the serum. *P < 0.05 or **P < 0.01 compared with SA group;
#P < 0.05 or ##P < 0.01 compared with CS group; †P < 0.05 or ††P < 0.01 compared with BM-MSCs group. Mean  S.E.M. are shown.
268 ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
269
J. Cell. Mol. Med. Vol 21, No 2, 2017
cells than BM-MSCs-CdM group (P < 0.01), indicating a better anti-
apoptotic effect of iPSC-MSCs-CdM. The release of cytochrome c
from mitochondria and its translocation to nucleus marks a major
event leading to the onset of apoptosis [28–30]. In this study, the per-
centage of cells with cytochrome c translocation was significantly
increased by the 2% CSM treatment (73.4  6.8% versus
1.88  1%; P < 0.01; Fig. 3A and D), which was attenuated by either
BM-MSCs-CdM (41.2  6.3%; P < 0.01 in comparison to CSM
group) or iPSC-MSCs-CdM (16.6  5%; P < 0.01 in comparison to
CSM group; Fig. 3D). iPSC-MSCs-CdM demonstrated a greater effect
compared with BM-MSCs-CdM (P < 0.01; Fig. 3D).
In addition to the effect on apoptosis, 2% CSM treatment also sig-
nificantly reduced the proliferation of the cells, indicated by significantly
reduced Ki-67-positive cell number in the population (3.4  0.5% ver-
sus 19.2  0.8%; P < 0.01; Fig. 3C and F). Both BM-MSCs-CdM
(8.2  0.6%; P < 0.01 in comparison to CSM group) and iPSC-MSCs-
CdM (13.4  0.5%; P < 0.01 in comparison to CSM group) were able
to reverse such reduction (Fig. 3F). Again, iPSC-MSCs-CdM showed a
superior effect than BM-MSCs-CdM (P < 0.1; Fig. 3F).
Amelioration of CSM-induced apoptosis/
proliferation imbalance was SCF-dependent in
BEAS-2B cells
Given the superior anti-apoptotic and pro-proliferative effect of iPSC-
MSCs-CdM than BM-MSCs-CdM, we further elucidated the compo-
nents in the CdM that induced such an effect. In particular, we were
interested in SCF which has been demonstrated to attenuate vascular
smooth muscle apoptosis [31]. In this case, the concentration of SCF
in CdM was determined, showing that iPSC-MSCs released much
higher level of SCF than BM-MSCs (518  57 versus 113  13 pg/
mg protein; P < 0.01; Fig. 4A). The expression of SCF receptor, c-Kit,
was also observed via immunofluorescent staining (Fig. 4B) and
Western blotting (Fig. 4C) in BEAS-2B cells. The data illustrated that
expression of c-Kit did not alter after CSM treatment (Fig. 4C).
To elucidate the role of SCF, SCF in iPSC-MSCs-CdM was scav-
enged by SCF antibody. BEAS-2B cells were treated with 2% CSM
together with iPSC-MSCs-CdM, SCF-deprived iPSC-MSCs-CdM or
human recombinant SCF for 24 hrs. All of the three treatments atten-
uated CSM-induced morphological change (Fig. 5A), cytochrome c
translocation (22.0  2.1%, 42.4  2.5% and 41.8  1.9% for
iPSC-MSCs-CdM, SCF-deprived group, and recombinant SCF group,
respectively, P < 0.01 for each group compared to CSM group
74.8  2.9%; Fig. 5B and E), apoptosis (5.6  0.5%, 10.4  0.5%
and 10.2  1.0%, respectively, P < 0.01 compared to CSM group
20  1.7%; Fig. 5C and F) and reduction in proliferation
(15.4  0.5%, 11.0  0.5% and 11.0  0.9%, respectively,
P < 0.01 compared to CSM group 5.8  0.4%; Fig 5D and G). Com-
pared with the iPSC-MSCs-CdM treatment, SCF-deprived iPSC-MSCs-
CdM led to significantly weakened activity, as indicated by more cyto-
chrome c translocation (P < 0.01), more apoptosis (P < 0.01) and
less proliferation (P < 0.01). This observation, in combination with
the finding that human recombinant SCF was able to induce consider-
able anti-apoptotic and pro-proliferative effects by itself, suggested
that SCF plays a role in the activity of iPSC-MSCs-CdM. Nevertheless,
the human recombinant SCF was not as effective as the iPSC-MSCs-
CdM regarding cytochrome c translocation (P < 0.01), apoptosis
(P < 0.01) and proliferation (P < 0.01). Given that the SCF-deprived
iPSC-MSCs-CdM still retained some capacity to restore all three
parameters, these data indicated that in addition to SCF, there should
be other components promoting similar effects. The action of iPSC-
MSCs-CdM to alleviate CSM-induced apoptosis/proliferation imbal-
ance was partly dependent on SCF in BEAS-2B cells.
Discussion
This study demonstrated that iPSC-MSCs could ameliorate CS-
induced macrophage/neutrophil infiltration and apoptosis/prolifera-
tion imbalance in rat lungs, in line with the attenuation of CSM-
induced apoptosis and the reversal of reduction in proliferation using
iPSC-MSCs-CdM in bronchial epithelial cells in vitro. Deprivation of
SCF from iPSC-MSCs-CdM led to reduced efficacy, indicating that the
action was partly mediated by SCF.
Currently, no medication is able to attenuate the progressive
decline of lung function in COPD [32]. As COPD is predicted to be the
fourth leading cause of death by 2030 [4] associated with enormous
economic and social burden, seeking new treatments for COPD is an
urgent and important task. MSCs from BM, adipose or cord blood
have been demonstrated to attenuate emphysema induced by CS,
elastase or VEGF deficiency [21, 33–37]. This led to a double-blind,
placebo-controlled phase II clinical trial of systemic administrations
of BM-MSCs to moderate or severe COPD patients [38]. However,
BM-MSCs did not improve lung function or quality of life indicators of
the patients compared with the placebo group in the trial. The results
point out the possibility that BM-MSCs might not be effective in the
clinical setting, despite the efficacy reported in various animal
Fig. 2MSCs ameliorated CS-induced apoptosis/proliferation imbalance in rat lungs. Rats (SA: n = 8, CS: n = 6, BM-MSCs: n = 7, iPSC-MSCs:
n = 7) were exposed to 4% CS 1 hr/day for 56 days. 3 9 106 BM-MSCs or iPSC-MSCs were injected at days 29 and 43. (A) Apoptotic cells in alve-
oli of lung sections. Green (TUNEL): apoptotic cells; blue (DAPI): nuclei. (B) Proliferative cells in alveoli of lung sections. Red: Ki-67; blue (DAPI):
nuclei. (C) Ratio of apoptotic cells in alveolus in lung sections. (D) Ratio of proliferative cells in lung sections. (E) Apoptotic cells in airway epithe-
lium. Red (CC-10): airway epithelium; green (TUNEL): apoptotic cells; blue (DAPI): nuclei. (F) Illustration of cell proliferation in airway epithelium.
Green (CC-10): airway epithelium; red (Ki-67): proliferative cells; blue (DAPI): nuclei. (G) Ratio of apoptotic cells in airway epithelium. (H) Ratio of
proliferative cells in airway epithelium. **P < 0.01 compared with SA group; ##P < 0.01 compared with CS group; ††P < 0.01 compared with
BM-MSCs group. Mean  S.E.M. are shown.
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Fig. 3 CdM from BM-MSCs and iPSC-MSCs ameliorated CSM-induced apoptosis/proliferation imbalance in BEAS-2B cells. BEAS-2B cells were trea-
ted with 2% CSM and BM-MSCs-CdM or iPSC-MSCs-CdM for 24 hrs. (A) Cytochrome c translocation in BEAS-2B cells. Green: cytochrome c; blue:
DAPI. Cells with cytochrome c translocation to nuclei are marked by red arrows and cells without cytochrome c translocation to nuclei are marked
by white arrows. (i) Cytochrome c channel, (ii) DAPI channel and (iii) merged image of a healthy cell. It is clear that the nucleus is negative for the
cytochrome c staining. (iv) Cytochrome c channel, (v) DAPI channel and (vi) merged image of a cell with nuclear translocation of cytochrome c. It
is clear that the nucleus region is now also positive for cytochrome c. (B) Apoptotic BEAS-2B cells as stained by TUNEL. Green: TUNEL; blue: DAPI.
(C) Proliferative BEAS-2B cells as marked by Ki-67. Red: Ki-67; blue: DAPI. (D) Percentage of BEAS-2B cells with cytochrome c translocation
(n = 3). (E) Percentage of apoptotic BEAS-2B cells (n = 3). (F) Percentage of proliferative BEAS-2B cells. **P < 0.01 compared with control group;
##P < 0.01 compared with CSM group; ††P < 0.01 compared with BM-MSCs-CdM group. Mean  S.E.M. are shown.
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models. Such findings call for searching for improved MSCs thera-
pies. After all, the trial demonstrated great safety of BM-MSCs in
patients with moderate or severe COPD in the 2-year follow-up, leav-
ing the door open for future trials.
The in vitro differentiation of iPSCs into MSCs provides a new
source of MSCs, which brings potential opportunities to overcome
several limitations of adult MSCs as seen in BM-MSCs. First, iPSC-
MSCs have a greater expansion capacity, maintaining differentiation
potential and normal karyotypes for 120 doublings, while BM-MSCs
get senescent after 20 doublings [11]. Second, BM-MSCs may pre-
sent reduced survival and differentiation ability when isolated from
aged subject or patients with ageing-related disorders [12–15].
iPSC-MSCs may overcome the ageing-associated impairment of BM-
MSCs, which may be important in COPD wherein the prevalence,
morbidity and mortality are related to age [16–18]. To generate
iPSC-MSCs, somatic cells were first reprogrammed to an embryonic
stem cell-like state, which may help to rejuvenate the cells and over-
pass the problem of senescence. Indeed, the telomerase activity of
iPSC-MSCs is 10 times higher compared with BM-MSCs [11]. Third,
individual adult MSC types like BM-MSCs may still present a hetero-
geneous group of cells of different subtypes [39]. This intra-popula-
tion heterogeneity is a limitation of MSCs-based therapy as current
understanding of functional attributes of MSCs at the population
level is still limited [39]. The iPSC-MSCs may represent a more
homogenous population as they grew from a single iPSC-MSC. Our
study represented a comparison between a preparation of iPSC-
MSCs and a preparation of BM-MSCs. It is hard to tell if the superior
effect of iPSC-MSCs was due to the higher ‘purity’ of active MSCs.
But such comparison mimics a comparison of potential therapeutic
applications, because the same issue exists in a clinical context. We
have previously demonstrated that iPSC-MSCs possessed a superior
capacity than BM-MSCs in attenuating CS-induced emphysema in
rats [20].
The time-points chosen in the animal model of this study were
based on our previous study [20]. As 28-day CS exposure can induce
moderate lung damage already, the rats were exposed to CS alone
but received no MSCs treatment, mimicking clinical situation as an
intervention. Based on our pilot study, CS cessation would recover a
few parameters used to define the lung damage in the model. There-
fore, the CS exposure was kept for another 28 days during the MSCs
treatment to maintain the oxidative stress and inflammation. In the
clinical trial of MSCs in COPD, the patients received MSCs infusion
every month for 4 months [38], while in another clinical trial of MSCs
in pulmonary fibrosis, MSCs were given every week for 1 month [40],
in line with the frequency of injection in this study.
Mesenchymal stem cells express very low levels of major histo-
compatibility complex class I and class II molecules, which makes
them highly immunologically tolerant [33, 41–43]. Exogenous
administration of allogeneic MSCs usually leads to low levels of
immune rejections and does not require immunosuppression. In
this study, human MSCs were injected into rats and no immuno-
logical rejection was observed [8]. The efficacy of human iPSC-
MSCs in rodent models of limb ischaemia, allergic inflammation
and emphysema was observed. It has also been reported by other
groups that both mouse and human adult adipose MSCs were able
to attenuate emphysema in mouse models [37]. Despite the use of
humanized mouse model, the study proved that human MSCs
worked very well on mouse tissues. Based on the immune-tolerant
property of MSCs, it may not be necessary to avoid immunological
rejection by using the humanized model.
Fig. 4 Secretion of SCF by BM-MSCs and iPSC-MSCs and expression of c-Kit by BEAS-2B cells. (A) SCF levels in CdM from BM-MSCs or iPSC-
MSCs as measured by ELISA (n = 3). (B) Illustration of c-Kit in BEAS-2B cells as identified by immunofluorescent staining with or without 2% CSM
treatment for 24 hrs. (C) c-Kit levels in BEAS-2B cells by Western blotting. Red: c-Kit; blue: DAPI. **P < 0.01 compared with BM-MSCs-CdM group.
Mean  S.E.M. are shown.
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Chronic inflammation is profiled in COPD especially in the small
airways [44], and the severity of the disease is correlated to the
degree of inflammation [45]. In this study, we demonstrated better
efficacy of iPSC-MSCs to reduce CS-induced infiltration of macro-
phages and neutrophils in comparison to BM-MSCs. Interleukin
(IL)-8, a potent chemoattractant for neutrophil recruitment [46], is a
biomarker of neutrophilic inflammation in COPD, with increased levels
in sputum and plasma in COPD patients in correlation to the severity
[47]. Cytokine-induced neutrophil chemoattractant-1 is the rat homo-
logue to human IL-8, acting as a major neutrophil chemoattractant
and activator in rats [48, 49]. In this study, iPSC-MSCs were able to
attenuate the CS-induced elevation of serum CINC-1 levels. As
inflammation is associated with oxidative stress in COPD, we further
measured the serum levels of 8-isoprostane, a by-product of lipid
peroxidation and a biomarker of oxidative stress [50]. Elevated 8-iso-
prostane levels in breath and urine have been found among patients
with COPD [51, 52]. In this study, iPSC-MSCs, but not BM-MSCs,
reduced serum 8-isoprostane in comparison to CS group, indicating
that the effect of iPSC-MSCs on macrophage/neutrophil infiltration
might be associated with effect on oxidative stress.
There are now mounting data suggesting that disturbance of the
balance between apoptosis and proliferation plays an important role
in the gradual destruction of alveolar structure in COPD [7]. Cigarette
smoke is reported to affect apoptosis of various cell types in the lung,
such as endothelial cells, alveolar epithelial cells, fibroblasts and
immune cells [7]. Excess apoptosis in alveolar cells of patients with
no compensation from increased proliferation results in the gradual
destruction of alveolar walls and finally leads to emphysema [7]. In
some animal models, emphysema can be induced by apoptosis of
alveolar wall and endothelial cells, even without the infiltration of
inflammatory cells [7]. In our previous study, iPSC-MSCs attenuated
CS-induced emphysema in rats [20]. Here, we further demonstrated
that CS exposure led to increased apoptosis and reduced proliferation
in lung epithelium, which was alleviated by treatment with iPSC-MSCs
or BM-MSCs. iPSC-MSCs demonstrated superior anti-apoptotic and
pro-proliferative effects in comparison to BM-MSCs.
Currently, there is only limited understanding about the mecha-
nism of MSCs’ action [21]. We previously reported mitochondrial
transfer to epithelium as one mechanism [20]. The limitation of this
mechanism is that mitochondrial transfer relies on direct contact
between iPSC-MSCs and airway cells. Although we observed the
retention of MSCs in lung even 2 weeks after injection [20], it is unli-
kely that they can reach every cell to take effect. The paracrine effect
of MSCs has been documented in various studies, many active
factors being identified, such as VEGF, transforming growth factor-
b1, hepatic growth factor, basic FGF- and platelet-derived growth fac-
tor [21]. While most studies of paracrine effects were focused on
immunoregulation [21], one previous report demonstrated that BM-
MSCs reduced CSM-induced apoptosis in a human umbilical vein
endothelial cell line partly through release of VEGF [34]. In our current
study, CdM from MSCs reduced the CSM-induced apoptosis of
BEAS-2B cells, which might result from the attenuation of CSM-
induced cytochrome c release from mitochondria and its transloca-
tion, an event that is reported to initiate cellular apoptosis [28–30].
This implies that MSCs may be able to attenuate CS-induced cyto-
chrome c translocation in the lung epithelium, leading to attenuation
of CS-induced apoptosis seen in our in vivo model. This is in support
of our previous report that MSCs attenuate CS-induced airspace
enlargement in rat lung [20]. While apoptosis was induced by CS, the
proliferation activity was reduced in BEAS-2B cells, indicating an
imbalance of the equilibrium between apoptosis and proliferation. The
CdM from MSCs reversed the CSM-induced reduction in proliferation,
leading to the restoration of the apoptosis/proliferation imbalance.
iPSC-MSCs-CdM demonstrated higher ability than BM-MSCs-CdM in
all the observed effects, suggesting a higher anti-apoptotic and pro-
proliferative capacity of iPSC-MSCs through paracrine action.
Stem cell factor is a dimeric protein that can mediate cell survival,
migration and proliferation through binding to its receptor, tyrosine
kinase c-Kit [22]. The SCF/c-Kit signalling is essential to maintain nor-
mal alveolar structure in mice. Deficiency in c-Kit signalling is
reported to result in spontaneous airspace enlargement, increased
ex vivo lung compliance and enlarged residual volume in mice [53].
In this study, BM-MSCs and iPSC-MSCs secreted SCF with the pres-
ence of c-Kit in BEAS-2B cells whose level of c-Kit was not changed
by CSM treatment. We found that SCF by itself was able to attenuate
CSM-induced apoptosis, cytochrome c translocation and reduction in
proliferation in BEAS-2B cells, while deprivation of SCF significantly
reduced capacity of iPSC-MSCs-CdM to achieve such effects. Such
data suggest that SCF plays an important role in the action of CdM.
However, the effects of SCF alone were much weaker than iPSC-
MSCs-CdM, and the SCF-deprived iPSC-MSCs-CdM was still capable
to reduce the apoptosis and restore the proliferation, indicating that
the action of iPSC-MSC-CdM was only partly through SCF. In addi-
tion, iPSC-MSCs secreted significantly higher level of SCF compared
with BM-MSCs, which may explain the superior anti-apoptotic and
pro-proliferative effects of iPSC-MSCs-CdM.
Nevertheless, there are some limitations in this study. First, the
in vivo study may not be able to fully mimic the clinic scenario
Fig. 5 The anti-apoptotic and pro-proliferative activity of iPSC-MSCs-CdM was partly through SCF. Immobilized anti-SCF antibody was used to scav-
enge SCF from iPSC-MSCs-CdM. BEAS-2B cells were treated with 2% CSM and iPSC-MSCs-CdM, SCF-deprived iPSC-MSCs-CdM or human recombi-
nant SCF for 24 hrs before fixation and TNUEL staining or immunofluorescent staining against cytochrome c and Ki-67 (n = 3). (A) The
morphological change of the BEAS-2B cells. DIC: differential interference contrast. (B) Cytochrome c translocation in BEAS-2B cells. Green: cyto-
chrome c; blue: DAPI. Cells with cytochrome c translocation to nuclei are marked by red arrows, and cells without cytochrome c translocation to
nuclei are marked by white arrows. (C) Apoptotic BEAS-2B cells as stained by TUNEL. Green: TUNEL; blue: DAPI. (D) Proliferative BEAS-2B cells as
marked by Ki-67. Red: Ki-67; blue: DAPI. (E) The percentage of BEAS-2B cells with cytochrome c translocation to nuclei (n = 3). (F) The percentage
of apoptotic BEAS-2B cells (n = 3). (G) The percentage of proliferative BEAS-2B cells (n = 3). **P < 0.01 compared with control group; ##P < 0.01
compared with CSM group; ††P < 0.01 compared with normal iPSC-MSCs-CdM group. Mean  S.E.M. are shown.
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because of the cross-species nature. Developing protocols for deriva-
tion of rat iPSC-MSCs and testing their effects in the rat model may
be a future step. Second, in the in vivo study, as the measurements
for inflammation and oxidative stress are not comprehensive before
looking into apoptosis/proliferation imbalance, the status of oxidative
stress and inflammation can be further investigated. Third, CdM was
directly collected from normal culture of iPSC-MSCs or BM-MSCs
which did not have interactions with the BEAS-2B cells. However, in a
paracrine crosstalk, BEAS-2B cells may release cytokines that can act
on MSCs to affect secretion of molecules from MSCs. In the in vivo
model, when MSCs circulated around the body, they will also interact
with the microenvironment around them. Such effects need to be fur-
ther investigated. Lastly, this study showed the contribution of SCF to
the anti-apoptotic and pro-proliferative effects, but the deprivation of
SCF did not completely eliminate the anti-apoptotic and pro-prolifera-
tive activity of the CdM, suggesting the involvement of other active
molecules that need to be determined in the future.
In conclusion, our data indicated that SCF partly mediated the
activity of iPSC-MSCs to ameliorate CS-induced apoptosis/prolifera-
tion imbalance in airway cells through paracrine effects. The higher
level of SCF in iPSC-MSCs-CdM over BM-MSCs-CdM may explain the
better anti-apoptotic and pro-proliferative capacity in the in vivo and
in vitro models of CS-induced airway cell injury. Our findings further
support iPSC-MSCs as a promising candidate in cell-based therapy
for the intervention of smoking-related COPD.
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